Phathom Pharmaceuticals, Inc. (PHAT)

Sentiment-Signal

18,9

Stark Bearisch

Composite Score (0–100)

Insider (25%)

Keine Insider-Käufe

Institutionell (22,5%)

Keine neuen Positionen

Aktivist (12,5%)

Kein 13D/13G

Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)

Score-Verlauf (90 Tage)

Stammdaten

Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

Unternehmen & Branche

Name	Phathom Pharmaceuticals, Inc.
Ticker	PHAT
CIK	0001783183
Boerse	US
Sektor	Healthcare
Industrie	Biotechnology
SIC	2834 · Pharmaceutical Preparations

Wertpapier & Kennzahlen

CUSIP	–
ISIN	–
Typ	Common Stock
Marktkapitalisierung	963,5 Mio. USD
Beta	0,61
Dividendenrendite	0,00 %

Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »

Finanzkennzahlen (SEC XBRL)

Periode	Filing	Umsatz	Nettoergebnis	EPS	Aktiva	Eigenkapital
2025-12-31	10-K	175,110,000	-221,247,000	-3.03	259,149,000	-438,169,000
2025-09-30	10-Q	49,504,000	-29,973,000	-0.41	240,289,000	-422,534,000
2025-06-30	10-Q	39,503,000	-75,810,000	-1.05	250,220,000	-405,834,000
2025-03-31	10-Q	28,519,000	-94,316,000	-1.31	294,208,000	-338,376,000
2024-12-31	10-K	55,252,000	-334,326,000	-5.29	378,318,000	-253,580,000
2024-09-30	10-Q	16,352,000	-85,577,000	-1.32	387,044,000	-187,112,000
2024-06-30	10-Q	7,324,000	-91,446,000	-1.56	319,376,000	-233,829,000
2024-03-31	10-Q	1,912,000	-82,852,000	-1.42	356,499,000	-148,503,000
2023-12-31	10-K	682,000	-201,592,000	-3.93	413,842,000	-72,759,000
2023-09-30	10-Q	0	-43,243,000	-0.76	236,992,000	-17,773,000
2023-06-30	10-Q	0	-40,965,000	-0.84	265,039,000	17,600,000
2023-03-31	10-Q	0	-37,814,000	-0.89	144,010,000	-90,195,000
2022-12-31	10-K	0	-197,723,000	-5.05	164,810,000	-74,814,000
2022-09-30	10-Q		-51,091,000	-1.32	201,931,000	-26,423,000
2022-06-30	10-Q		-50,920,000	-1.33	213,502,000	-7,000,000
2022-03-31	10-Q		-40,665,000	-1.07	149,049,000	38,035,000
2021-12-31	10-K		-143,883,000	-3.89	189,431,000	72,156,000
2021-09-30	10-Q		-36,662,000	-0.98	228,377,000	103,481,000
2021-06-30	10-Q		-36,552,000	-1.00	214,579,000	132,128,000
2021-03-31	10-Q		-34,843,000		246,363,000	164,339,000

Fondsaktivität (Vorquartalsvergleich)

Keine Fondsdaten für dieses Unternehmen vorhanden.

Insider-Transaktionen (12 Monate)

Datum	Insider	Rolle	Typ	Stückzahl	Kurs	Wert (USD)	Δ
2025-11-03	Breedlove Robert Charles	Officer, Principal Accounting Officer	Open Market Sale	-524	13.51	-7,079.24	-31,9%
2025-09-05	Breedlove Robert Charles	Officer, Principal Accounting Officer	Open Market Sale	-461	12.09	-5,573.49	-25,1%
2025-07-16	Breedlove Robert Charles	Officer, Principal Accounting Officer	Open Market Sale	-1,692	8.36	-14,151.72	-63,9%
2025-05-21	Topper James N	Director	Open Market Purchase	3,780	3.86	14,609.32	+65,9%
2025-05-14	Topper James N	Director	Open Market Purchase	6,300	3.32	20,919.15	+94,4%
2025-05-13	Topper James N	Director	Open Market Purchase	1,120	3.16	3,543.34	+16,0%
2025-05-12	Topper James N	Director	Open Market Purchase	12,601	3.04	38,300.74	+172,8%
2025-05-09	Topper James N	Director	Open Market Purchase	33,376	3.19	106,562.89	+480,8%
2025-05-09	Topper James N	Director	Open Market Purchase	2,226	3.62	8,053.00	+36,3%
2025-05-07	Parikh Asit	Director	Open Market Purchase	5,000	2.40	11,984.50	+54,1%
2025-05-06	Parikh Asit	Director	Open Market Purchase	5,000	2.60	13,000.00	+58,7%

Top-Fondshalter

Keine Fondsdaten zu dieser Aktie vorhanden.